EMA finalises first set of guidelines on good pharmacovigilance practice ahead of 2 July deadline
This article was originally published in SRA
The European Medicines Agency has finalised its first ever set of guidance documents on good pharmacovigilance practices (GVP) to help drug companies comply with the provisions of the new EU pharmacovigilance legislation that will apply from 2 July1.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.